Lytix Biopharma (Q4 Review): Well-Funded to Deliver in 26′ - Redeye

Redeye comments on Lytix' third quarter report 2025. After the quarter, NOK77m was raised in a directed and rights issue. This provides the company with a prolonged runway into 2027 after the NeoLipa readout in H2 2026. Verrica raised USD50m, providing it a runway into mid-2027.

Länk till analysen i sin helhet: https://www.redeye.se/research/1149495/lytix-biopharma-q4-review-well-funded-to-deliver-in-26?utm_source=finwire&utm_medium=RSS